Impact of MiRSNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Purpose: A distinctive new group of polymorphisms is constituted by single-nucleotide polymorphism (SNP) in miRNA processing machinery in miRNA precursor molecules and in miRNA-binding sites, known as miRSNPs. The aim of this study was to ascertain the prognostic impact of six miRSNPs in patients with multiple myeloma and analyze the functional consequences. Experimental Design: One hundred and thirty-seven patients with chemosensitive multiple myeloma (73M/64F) intensified with autologous stem cell transplantation (ASCT) were studied. The median follow-up was 4 years. The genes and SNPs evaluated in genomic DNA by allelic discrimination were KRT81 (rs3660), AFF1 (rs17703261), FAM179b (rs1053667), and MIR196A2 (rs11614913) for miRNA target genes and TRBP (rs784567) and XPO5 (rs11077) for miRNA biogenesis pathway. Results: Overall survival (OS) was significantly longer in patients with KRT81 rs3660 C/C variant (P = 0.037). Functional analysis showed that the presence of C variant in KRT81 3′ untranslated region (UTR) is related with a reduction of the protein levels. Moreover, the reduction of KRT81 protein levels by siRNA in multiple myeloma cell lines is related to a decreased proliferation. On the other hand, OS was significantly longer in patients with C/C or A/C variant in XPO5 rs11077 (P = 0.012). There was also a significantly longer progression-free survival (PFS) for this SNP (P = 0.013). This SNP retained its prognostic impact on PFS and OS in a multivariate regression analysis (P = 0.028 and P = 0.014, respectively). Conclusion: This is the first report that relates miRSNPs with prognosis in multiple myeloma either in a keratin gene (KRT81), target of diverse miRNA multiple myeloma clusters, or in the miRNA biogenesis pathway–related protein exportin-5. Clin Cancer Res; 18(13); 3697–704. ©2012 AACR.

[1]  C. Harris,et al.  Genetic variation in microRNA networks: the implications for cancer research , 2010, Nature Reviews Cancer.

[2]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[3]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[4]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[5]  J. Rivas,et al.  Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling , 2010, Leukemia.

[6]  B. Barlogie,et al.  Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Bladé,et al.  2010 Hematopoietic stem cell transplantation for multiple myeloma beyond , 2011 .

[8]  J. Gimferrer,et al.  Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer. , 2011, The Journal of surgical research.

[9]  Jun Shi,et al.  Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens , 2011, Haematologica.

[10]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[11]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[12]  S. Tavtigian,et al.  Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan , 2010, Bone Marrow Transplantation.

[13]  Edwin Wang,et al.  Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers , 2007, Nucleic acids research.

[14]  Jian Gu,et al.  Genetic Variations in MicroRNA-Related Genes Are Novel Susceptibility Loci for Esophageal Cancer Risk , 2008, Cancer Prevention Research.

[15]  V. Kim.  MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[16]  C. Harris,et al.  Genetic variation in microRNA networks: the implications for cancer research , 2010, Nature Reviews Cancer.

[17]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[18]  J. Esteve,et al.  Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. , 2006, Blood.

[19]  Hiroyuki Yamamoto,et al.  A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. , 2010, Cancer cell.

[20]  D. Gudbjartsson,et al.  New common variants affecting susceptibility to basal cell carcinoma , 2009, Nature Genetics.

[21]  J. Bladé,et al.  Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. , 2010, Blood.

[22]  J. Harousseau.  Hematopoietic stem cell transplantation in multiple myeloma. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[24]  V. Karantza,et al.  Keratins in health and cancer: more than mere epithelial cell markers , 2011, Oncogene.

[25]  H. Sugerman,et al.  Association between Incident Cancer and Subsequent Stroke , 2015, Annals of neurology.

[26]  E. Bandrés,et al.  Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan , 2011, The Pharmacogenomics Journal.

[27]  L. Escoda,et al.  Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.